Spots Global Cancer Trial Database for incagn01876
Every month we try and update this database with for incagn01876 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| Biomarker-based Study in R/M SCCHN | NCT03088059 | Carcinoma, Squa... | Afatinib Palbociclib standard of car... IPH2201 Durvalumab Niraparib INCAGN01876 | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors | NCT02697591 | Advanced Malign... Metastatic Canc... | INCAGN01876 | 18 Years - | Incyte Corporation | |
| Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC | NCT04470024 | Cancer of the H... | INCAGN01876 INCMGA00012 DPV-001 | 18 Years - | Providence Health & Services | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | NCT04225039 | Glioblastoma | INCMGA00012 INCAGN01876 SRS Brain surgery | 18 Years - | University of Pennsylvania | |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT05359692 | Metastatic Head... Advanced Malign... Recurrent Head ... | INCAGN01876 retifanlimab | 18 Years - 99 Years | Incyte Corporation | |
| Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | NCT04225039 | Glioblastoma | INCMGA00012 INCAGN01876 SRS Brain surgery | 18 Years - | University of Pennsylvania | |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | NCT03277352 | Advanced Malign... Metastatic Canc... | INCAGN01876 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | NCT04225039 | Glioblastoma | INCMGA00012 INCAGN01876 SRS Brain surgery | 18 Years - | University of Pennsylvania |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
